anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nitrocellulose compositions comprise 5-15 parts of nitrocellulose, 2-15 parts of castor oil, 2-10 parts of methyl cellusolve, and a mixture of ethanol and ethyl ether in such proportions as to bring the total amount of the composition up to 106 parts by weight.  An exemplified composition contains 10 parts of nitrocellulose, 5 parts of castor oil, 5 parts of methyl cellosolve and 86 parts of a mixture of ethanol and ethyl ether. This mixture consists of 47 parts of 95 per cent ethanol, 42 parts of ether and 11 parts of the vehicle or carrier with which the nitrocellulose was originally mixed, said vehicle consisting of ethanol or a 75/25 v/v ethanol-ether ether mixture.  The number of parts of castor oil in 106 parts of the composition is preferably 3-10, and up to 80 per cent of the castor oil may be replaced by camphor.  The compositions may also contain butyl, pentyl or hexyl acetate, ketones or the acetic acid ester of 2 methoxy ethanol. The compositions are for use as cosmetics for applying to the face to form a contractile film which alters the contour of the portion of the face to which the film has been applied.ALSO:Liquid cosmetic preparations, for forming a transparent colourless film for holding the skin in moulded contour, comprise 5-15 parts of nitrocellulose, 2-15 parts of castor oil, 2-10 parts of methyl cellosolve and a mixture of ethanol and ethyl ether in such proportions as to bring the total amount of the composition up to 106 parts by weight.  An exemplified composition contains 10 parts of nitrocellulose, 5 parts of castor oil, 5 parts of methyl cellosolve and 86 parts of a mixture of ethanol and ethyl ether.  This mixture consists of 47 parts of 95 per cent ethanol, 42 parts of ether and 11 parts of the vehicle or carrier with which the nitrocellulose was originally mixed, said vehicle consisting of ethanol or a 75/25 V/V ethanol-ethyl ether mixture.  The number of parts of castor oil in 106 parts of the composition is preferably 3-10, and up to 80 per cent of the castor oil may be replaced by camphor.  The compositions may also contain butyl, pentyl or hexyl acetate, ketones or the acetic acid ester of 2 methoxy ethanol.
PURPOSE: To obtain an anhydrous cosmetic makeup compsn. contg. a fat phase mixed with a provesicle lipid phase capable of forming vesicles in the presence of water. CONSTITUTION: A fat phase consisting of oil, a fat base and a surfactant is mixed with a provesicle lipid phase contg. at least one kind of amphipatic lipid capable of forming vesicles by contact with an aq. phase. The amphipatic lipid is, e.g. ionic amphipatic lipid represented by the formula (R1 is 7-21C alkyl or alkenyl, R2 is a residue of satd. or unsatd. 7-31C hydrocarbon and M is H, Na, K, NH4 or an ammonium ion derived from an amine) or nonionic amphipatic lipid such as straight chain or branched chain polyglycerol ether having two aliphatic chains, aliphatic alcohol having polyoxyethylene, natural or synthetic glycolipid. It is preferably that a cosmetically active material or a dermatologically active material is further incorporated into the resultant anhydrous compsn.
The invention relates to a tumor radiotherapy sensitizer based on carbon dots and application thereof, which is characterized in that: the carbon dots have high biocompatibility and no damage to organs of a living body. Secondly, the carbon dots passively target tumor tissues by utilizing the EPR effect of the material, so that the cell cycle of tumor cells is arrested in a G2/M phase, and the proliferation of the tumor cells is inhibited. Carbon dots consume GSH at the tumor site and generate large amounts of ROS, promoting DNA damage to induce apoptosis in tumor cells. When the tumor cells are in the G2/M phase, the sensitivity to radiotherapy is higher. An increase in intracellular ROS levels may increase the intrinsic radiosensitivity of tumor cells. Based on the two characteristics, the carbon dots can enhance the sensitivity of radiation to tumor cells, and the purpose of tumor radiotherapy sensitization is achieved. In conclusion, the carbon dots can realize multiple efficacies of targeting tumor cells, inhibiting tumor cell proliferation and enhancing radiotherapy sensitivity, and have good application prospects.
Dofetilide is contraindicated in patients with congenital or acquired long QT syndromes. Dofetilide should not be used in patients with a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities). Dofetilide is also contraindicated in patients with severe renal impairment (calculated creatinine clearance <20 mL/min).

The concomitant use of verapamil or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), or ketoconazole with dofetilide is contraindicated (see WARNINGS and PRECAUTIONS, Drug-Drug Interactions), as each of these drugs cause a substantial increase in dofetilide plasma concentrations. In addition, other known inhibitors of the renal cation transport system such as prochlorperazine, dolutegravir and megestrol should not be used in patients on dofetilide. 

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. 

Dofetilide is also contraindicated in patients with a known hypersensitivity to the drug.
Disclosed is a transdermal preparation in which a basic anti-inflammatory agent is blended. The transdermal preparation is an adhesive patch for external use, which has excellent drug release properties without deteriorating the physical properties of the plaster. The transdermal preparation is capable of achieving high release properties for the basic anti-inflammatory agent without deteriorating the release properties for a local anesthetic. Specifically disclosed is an adhesive transdermal patch which is characterized by containing both a basic anti-inflammatory agent and a local anesthetic that serves as an absorption enhancer for the basic anti-inflammatory agent. The basic anti-inflammatory agent has an acid dissociation constant (pKa) of not less than 7. The basic anti-inflammatory agent is contained therein in an amount of 0.1-10% by weight relative to the total weight of the drug-containing plaster, and the absorption enhancer is contained therein in an amount of 0.01-20% by weight relative to the total weight of the drug-containing plaster.
Adolescents commonly co-abuse many drugs including anabolic androgenic steroids either they are athletes or non-athletes. Stanozolol is the major anabolic used in recent years and was reported grouped with cannabis. The current study aimed at evaluating the biochemical and histopathological changes related to the hypertrophic effects of stanozolol and/or cannabis whether in condition of exercise practice or sedentary conditions. Adult male Wistar albino rats received either stanozolol (5 mg/kg, s.c), cannabis (10 mg/kg, i.p.), and a combination of both once daily for two months. Swimming exercise protocol was applied as a training model. Relative heart weight, oxidative stress biomarkers, cardiac tissue fibrotic markers were evaluated. Left ventricular morphometric analysis and collagen quantification was done. The combined treatment exhibited serious detrimental effects on the heart tissues. It increased heart tissue fibrotic markers (Masson's trichrome stain (p < 0.001), cardiac COL3 (p < 0.0001), and VEGF-A (p < 0.05)), lowered heart glutathione levels (p < 0.05) and dramatically elevated oxidative stress (increased malondialdehyde (p < 0.0001) and 8-OHDG (p < 0.0001)). Training was not ameliorating for the observed effects. Misuse of cannabis and stanozolol resulted in more hypertrophic consequences of the heart than either drug alone, which were at least largely assigned to oxidative stress, heart tissue fibrotic indicators, histological alterations, and morphometric changes.
The invention belongs to the field of medicine, in particular to a ketoprofen slow release preparation. The slow release preparation can be used for solving the technical problems that blood concentration is stable after the preparation administration, and ketoprofen can be released stably within 24 hours. The slow release preparation comprises the following components in parts by weight: main drugs: 200 parts of ketoprofen, 110-120 parts of slow release skeleton matrix, hydroxyl methyl propyl cellulose (HPMC) K4M, and HPMC K100M, wherein ratio of the HPMC K4M to the HPMC K100M is equal to 5:1. Pharmaceutically-acceptable accessories are added to the main drugs to prepare the slow release preparation provided by the invention. The slow release preparation is mainly used for treating rheumatoid arthritis or rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, dysmenorrheal and the like, and also used for treating joint strain, soft tissue injury, fracture pain, postoperation pain and the like. By utilizing the slow release preparation, long-acting slow release can be realized, the peak value and valley value of the blood concentration can be reduced, the blood concentration is more stable, the eliminated half-life period is as long as 11 hours, especially stable release within 24 hours can be realized and the ketoprofen slow release preparation is taken only once in a day.
OBJECTIVE: We aimed to explore the efficacy and safety of efgartigimod in patients with refractory immune-mediated necrotizing myopathy (IMNM).
METHODS: This open-label pilot observational study included seven patients with refractory IMNM, all of whom received intravenous efgartigimod treatment. The clinical response was assessed after 4 weeks of efgartigimod treatment according to the 2016 American College of Rheumatology-European League Against Rheumatism response criteria for adult idiopathic inflammatory myopathy. Serum levels of immunoglobulin as well as anti-signal recognition particle (SRP) and anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) antibodies were measured using enzyme-linked immunosorbent assays and commercial line immunoblot assays. Safety assessments included evaluations of adverse events and severe adverse events.
RESULTS: The seven patients with refractory IMNM included five cases with anti-HMGCR antibodies and two cases within anti-SRP antibodies. Four of the seven patients achieved clinical responses. The total improvement score for the responders at 4 weeks were 32.5, 40.0, 47.5, and 70.0, and those at 8 weeks were 27.5, 47.5, 57.5, and 70.0. In comparison to the responsive patients, the non-responsive patients had longer durations [8 (-) versus 2 (1-5) years, P = 0.03], and more chronic myopathic features by muscle biopsy (67% versus 0%, P = 0.046). Serum immunoglobulin G levels (11.2 ± 2.5 versus 5.7 ± 2.5, P = 0.007) and anti-HMGCR/SRP antibody levels (97.2 ± 6.9 versus 41.8 ± 16.8, P = 0.002) were decreased after treatment compared with baseline levels. Adverse events were reported in one of the seven patients, who showed mild headache.
CONCLUSIONS: Despite its small size, our study demonstrated that promoting the degradation of endogenous immunoglobulin G may be effective for patients with IMNM. Efgartigimod may be a promising option for cases of refractory IMNM to shorten duration and minimize chronic myopathic features.
Raynaud's phenomenon is a disorder characterized by spasm of digital arteries leading to blanching, coldness and discomfort of the affected digit, affecting up to 3-5% of the population at some time in their lives. Raynaud's is roughly classified into primary and secondary forms. The primary form may occur without apparent cause or following such things as acute trauma, repetitive vibrating trauma or frostbite. Secondary Raynaud's occurs in association with a variety of systemic immunological diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SS) and Sjogren's syndrome. Perhaps the most severe forms are associated with systemic sclerosis, less often in SLE where severe microvascular changes can lead to digital ulcerations which are difficult to heal and produce considerable functional impairment Treatment of Raynaud's has been a significant clinical challenge. The primary modality is to avoid cold exposure. Many drug classes have been shown to have some, but highly variable and potential toxicities.

Diosmiplex is a prescription medical food product composed of the botanical based flavonoid molecule, diosmin, and a proprietary systemic blood alkalinizing agent, Alka4-complex. Diosmin has been used successfully in Europe as a drug for chronic venous insufficiency and its complications, including venous ulcers for more than 35 years. There is a large body of published literature regarding the molecular activity, clinical efficacy and safety of the active molecule in diosmin as well as its effects on the microvasculature where it has been shown to reduce inflammation, improve structural integrity, reduce capillary damage and improve capillary flow but no prospective clinical studies have been published regarding its effect in Raynaud's phenomenon. This will be the first prospective study to examine the efficacy and safety of diosmin, as diosmiplex, in both primary and secondary Raynaud's. The study will intentionally seek to enroll a subset of subjects with scleroderma with Raynaud's complicated by digital ulcers.

This will be a two (2) month randomized, double blind, placebo controlled study. Patients with either primary or secondary Raynaud's phenomenon present for at least 12 months and either untreated or inadequately controlled on therapy, defined as having at least four (4) vasospastic episodes/week, will be eligible for enrollment
In prostate cancer patients undergoing robot-assisted radical prostatectomy (RARP), the current European Association of Urology (EAU) prostate cancer guidelines recommend bilateral pelvic lymph node dissection (BPLND) for those with an estimated risk of occult nodal metastases exceeding 5%.(1) In a systematic review of 66 studies involving 275, 269 patients, lymphadenectomy can identify node positive patients who may benefit from adjuvant treatment (2).

BPLND in general is a well-tolerated procedure. However, when complications do occur, significant morbidity results. The benefits of BPLND must be carefully weighed against its potential complications. The most common complication of BPLND is lymphocoele formation. Lymphatic vessels have no muscular layer as opposed to blood vessels. Transection of a blood vessel will lead to vasoconstriction and eventual cessation of bleeding. This is not the case with lymphatic vessels, and transection will lead to prolonged lymphorrhoea. The incidence of lymphocoele varies from series to series, ranging from 0.8% to 33%, depending on the extent of lymphadenectomy, surgical technique, operative approach, and the diagnostic approach (3,4). The most common symptoms are pelvic pain, abdominal distension, lower extremity or scrotal oedema, lower urinary tract symptom, frank bladder outlet obstruction, sepsis and even anastomotic disruption. Prolonged lymphorrhoea lengthens hospital stay, places the patient at risk for nosocomial infection and has significant cost implications for the healthcare system.

Hemopatch is a haemostatic pad consisting of a collagen sheet derived from bovine dermis with an NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate) coated active surface. These two components act together to provide effective tissue adherence, sealing and haemostasis (5). Upon tissue contact, NHS-PEG molecules on the active surface form covalent bonds with tissue proteins. Cross-linking NHS-PEG and proteins forms a hydrogel which acts as an effective tissue seal. Older generation NHS-PEG products in the form of solutions of flowable sealants are quickly washed away by blood or other leaking body fluids, rendering them ineffective in the presence of active bleeding or fluid leakage. Hemopatch is a novel NHSPEG delivery vehicle designed to overcome this limitation. Due to the open pore structure of the collagen, excess tissue fluids are readily absorbed and direct contact of NHS-PEG to tissue surface can be achieved. The collagen pad is optimized to be soft, thin, pliable, and has a high liquid absorption capacity. The pad is resorbed and replaced by host tissue in six to eight weeks with little tissue reaction.

The investigators hypothesise that the application of Hemopatch to raw lymphatic tissue can prevent lymphorrhoea through its unique combination of tissue adherence, sealing and fluid absorption. This can potentially prevent lymphatic leak, reduce drain output and facilitate earlier discharge.
After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
The major aim of this study is to carry out a sequential Phase I trial of prefrontal transcranial magnetic brain stimulation (TMS) and electroconvulsive therapy (ECT) in patients with Parkinson's disease (PD) and severe depression. Depression complicates PD in up to 50% of cases, leading to further deterioration of motor performance and quality of life; but antidepressant medication fails or produces intolerable side effects in 25-30% of patients. Case reports and uncontrolled trials suggest that ECT is effective in ameliorating simultaneously the mood and motor symptoms of PD. Only a few small studies of ECT in PD have been prospective or randomized, the assessment protocols have been limited, and the results have been variable. TMS is a new, promising, alternative treatment for refractory depression, which appears to be easier and safer than ECT. Requiring no hospitalization, anesthesia, or recovery time, TMS is now being investigated as an alternative therapy for mood disorders. TMS has not been studied in depressed patients with PD or in other serious central nervous system diseases.

This study extends our past and present research in PD, depression, ECT, and TMS. We will comprehensively evaluate the effects of left prefrontal TMS on mood, motor, and neuropsychological function, together with quality of life indices in depressed PD patients. All patients will initially receive treatment with TMS. Those who fail to benefit will proceed to ECT. Comprehensive evaluation will be continued for another eight weeks in both the TMS-only and ECT groups. The key issues addressed by these studies include: (1) the potential benefit of TMS on mood and movement in depressed PD patients, and (2) the tightness of the association between mood and motor function after TMS and ECT. Overall, these studies will provide important preliminary data on the relationships among mood, cognitive and motor function in PD, and their influence on quality of life. The results will help in directing future applications of TMS as an alternative therapy for brain disorders, and will further elucidate the relative benefits of both TMS and ECT in depressed PD patients. A positive effect from TMS should be an impetus towards randomized, placebo-controlled trials.
Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Background and Objectives: Legionnaires' disease (LD) is an acute respiratory disease with increasing annual numbers of reported domestic and global cases. This study aimed to establish foundational data for the prevention and control of LD by investigating the occurrence and infection routes of reported and suspected cases of LD in Gyeonggi Province, Korea, from January 2016 to December 2022, and by and analyzing the risk factors for death. Materials and Methods: A sex-and-age standardization was performed on LD patients and suspected cases reported in Gyeonggi Province. The monthly average number of confirmed cases was visualized using graphs, and a survival analysis was performed using Kaplan-Meier survival curves. The mortality risk ratio was estimated using the Cox proportional hazards model. Results: The incidence of LD in Gyeonggi Province mirrored the national trend, peaking in July with the highest number of confirmed and suspected cases. While there was no significant difference in survival rates by age, the survival rate was higher for suspected cases when analyzed separately. Comparing the death ratio by infection route, nosocomial infections showed the highest death ratio, and intensive care unit (ICU) admission and the presence of coinfections were significantly correlated with mortality. Factors such as nosocomial infection, admission within 1 to 3 days following diagnosis, and the development of complications were factors contributing to a higher risk of death. Conclusions: The general characteristics of patients with LD were similar to those suggested by previous studies. The proportion of community-acquired infections was lower than in previous studies, but the length of hospital stay was similar for survivors and the deceased, and the mortality rate within 30 days after diagnosis was higher for nosocomial infections. In conclusion, nosocomial infection, a period of up to 3 days from admission to diagnosis, and complications were significantly related to the mortality rate of LD.
The invention discloses a fusion protein of hepatic-targeted peptide and human interferon a2b, and a preparation method and application thereof. The nucleotide sequence of the fusion protein of hepatic-targeted peptide and human interferon a2b provided in the invention is described by SEQ ID NO. 1, and the amino acid sequence coded by the nucleotide sequence is described by SEQ ID NO. 2. According to in vitro tests, the fusion protein provided in the invention has obvious activity of resisting HBV and hepatocyte targeting. Since characteristics of both hepatic-targeted peptide of plasmodium circumsporozoite protein CSPI-plus and human IFNa2b are combined into the fusion protein in the invention, the fusion protein can be used for preparation of novel hepatic-targeted antiviral drugs and is of profound significance for lowering down morbidity and mortality of liver diseases caused by infection of HBV. According to the invention, the prepared fusion protein has a high expression level and is easy to purify, production period for the fusion protein is short, and low cost is realized; therefore, the invention has important application prospects and is of practical significance.